Iovance climbs after FDA rejection for Replimune's skin cancer drug
Source: SeekingAlpha
2025-07-22 10:54:31 ET
More on Iovance Biotherapeutics, Replimune Group
- Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug
- Iovance Biotherapeutics: ASCO Update, Competitor Data And The Road Ahead
- Iovance: Amtagvi's Rocky Launch And Mounting Concerns Lead To A 'Sell' Rating
- Replimune says FDA rejected its lead drug for skin cancer
- Replimune Group GAAP EPS of -$3.07 misses by $0.01
Read the full article on Seeking Alpha
For further details see:
Iovance climbs after FDA rejection for Replimune’s skin cancer drug
Replimune Group Inc.
NASDAQ: REPL
REPL Trading
-10.42% G/L:
$4.6493 Last:
4,448,331 Volume:
$5.06 Open:
REPL Latest News
REPL Stock Data
$646,543,607
51,607,887
0.33%
61
N/A
Biotechnology & Life Sciences
Healthcare
US
Woburn
